Vigonvita Life Sciences Secures CSRC Green Light for 100.22 Million H-Share Full Circulation

Bulletin Express06-29

Vigonvita Life Sciences Co., Ltd. announced it has received a filing notice from the China Securities Regulatory Commission (CSRC) approving its H-share full-circulation application. The approval covers the conversion of 100.22 million unlisted domestic shares held by 10 existing shareholders into H shares.

Upon completion of the share conversion and subject to listing approval from Hong Kong Exchanges and Clearing Limited, the newly converted H shares will be admitted to trading on the Main Board of The Stock Exchange of Hong Kong. The CSRC filing notice remains valid for 12 months; should the conversion and listing extend beyond that period, the company must submit an updated filing.

Detailed implementation arrangements—including the conversion timetable—have yet to be finalized. Vigonvita stated it will release further updates in accordance with Hong Kong’s Listing Rules and inside-information provisions. The conversion process also requires additional procedures and approvals from both mainland and Hong Kong regulators.

The board is chaired by Dr. Tian Guanghui, who also serves as executive director, chief executive officer and general manager. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170174390?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170174390","market":"us","top_or_hot":-1,"title":"Vigonvita Life Sciences Secures CSRC Green Light for 100.22 Million H-Share Full Circulation","media":"Bulletin Express","content":"<p>Vigonvita Life Sciences Co., Ltd. announced it has received a filing notice from the China Securities Regulatory Commission (CSRC) approving its H-share full-circulation application. The approval covers the conversion of 100.22 million unlisted domestic shares held by 10 existing shareholders into H shares.</p>\n<p>Upon completion of the share conversion and subject to listing approval from Hong Kong Exchanges and Clearing Limited, the newly converted H shares will be admitted to trading on the Main Board of The Stock Exchange of Hong Kong. The CSRC filing notice remains valid for 12 months; should the conversion and listing extend beyond that period, the company must submit an updated filing.</p>\n<p>Detailed implementation arrangements—including the conversion timetable—have yet to be finalized. Vigonvita stated it will release further updates in accordance with Hong Kong’s Listing Rules and inside-information provisions. The conversion process also requires additional procedures and approvals from both mainland and Hong Kong regulators.</p>\n<p>The board is chaired by Dr. Tian Guanghui, who also serves as executive director, chief executive officer and general manager. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vigonvita Life Sciences Secures CSRC Green Light for 100.22 Million H-Share Full Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVigonvita Life Sciences Secures CSRC Green Light for 100.22 Million H-Share Full Circulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-29 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vigonvita Life Sciences Co., Ltd. announced it has received a filing notice from the China Securities Regulatory Commission (CSRC) approving its H-share full-circulation application. The approval covers the conversion of 100.22 million unlisted domestic shares held by 10 existing shareholders into H shares.</p>\n<p>Upon completion of the share conversion and subject to listing approval from Hong Kong Exchanges and Clearing Limited, the newly converted H shares will be admitted to trading on the Main Board of The Stock Exchange of Hong Kong. The CSRC filing notice remains valid for 12 months; should the conversion and listing extend beyond that period, the company must submit an updated filing.</p>\n<p>Detailed implementation arrangements—including the conversion timetable—have yet to be finalized. Vigonvita stated it will release further updates in accordance with Hong Kong’s Listing Rules and inside-information provisions. The conversion process also requires additional procedures and approvals from both mainland and Hong Kong regulators.</p>\n<p>The board is chaired by Dr. Tian Guanghui, who also serves as executive director, chief executive officer and general manager. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02630","symbol_name":"旺山旺水-B","start_time":0,"source_url":"","article_id":"1170174390","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170174390","pubTimestamp":1782727523,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Vigonvita Life Sciences Co., Ltd. announced it has received a filing notice from the China Securities Regulatory Commission (CSRC) approving its H-share full-circulation application. The approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02630":"旺山旺水-B"},"translate_title":"Vigonvita Life Sciences获得证监会批准10022万股H股全流通","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":1},"content_text":"Vigonvita Life Sciences Co., Ltd. announced it has received a filing notice from the China Securities Regulatory Commission (CSRC) approving its H-share full-circulation application. The approval covers the conversion of 100.22 million unlisted domestic shares held by 10 existing shareholders into H shares.\nUpon completion of the share conversion and subject to listing approval from Hong Kong Exchanges and Clearing Limited, the newly converted H shares will be admitted to trading on the Main Board of The Stock Exchange of Hong Kong. The CSRC filing notice remains valid for 12 months; should the conversion and listing extend beyond that period, the company must submit an updated filing.\nDetailed implementation arrangements—including the conversion timetable—have yet to be finalized. Vigonvita stated it will release further updates in accordance with Hong Kong’s Listing Rules and inside-information provisions. The conversion process also requires additional procedures and approvals from both mainland and Hong Kong regulators.\nThe board is chaired by Dr. Tian Guanghui, who also serves as executive director, chief executive officer and general manager. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170174390","isCrawlerRequest":true}